CYT
Cyteir Therapeutics, Inc. [CYT] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
CYT Stock Summary
In the News
CYT Financial details
Company Rating
-
Market Cap
108.71M
Income
-30.88M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
46
Optionable
No
Shortable
Yes
Earnings
28 Mar 2024
P/E
-3.56
Forward P/E
-
PEG
0.6
P/S
-
P/B
0.88
P/C
-
P/FCF
-4.21
Quick Ratio
21.66
Current Ratio
21.89
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.87
EPS next Y
-
EPS next Q
-
EPS this Y
-41.59%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-59.17%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-24%
ROE
-23%
ROC
-0.31%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.65-3.19
52W High
-
52W Low
-
RSI
-
Rel Volume
6.01
Avg Volume
167.62K
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
0.096
-
-
Volatility
0%, 0%
Prev Close
-
Price
-
Change
-
Company Profile
- Volume Average 167.62K
- Market Capitalization 108.71M
- Employee 46
- CEO Dr. Markus F. Renschler M.D.
- Headquarters Lexington,MA,US
- IPO Date 2021-06-18
-
Website
https://cyteir.com 
Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. The company is also developing CYT-1853, which is in preclinical trials for solid tumors and hematologic malignancies. The company was incorporated in 2012 and is based in Lexington, Massachusetts.
